Gastrointestinal Cancer: Research & Therapy is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Gastrointestinal Cancer.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Gastrointestinal Cancer. Gastrointestinal Cancer: Research & Therapy accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Gastrointestinal Cancer.
Gastrointestinal Cancer: Research & Therapy strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
The document discusses several controversies in treating recurrent ovarian cancer, including:
1) The role of monitoring CA-125 levels and whether chemotherapy should be initiated based on a rising CA-125 alone without other evidence of disease.
2) The potential benefit of secondary cytoreduction surgery for some patients with recurrent disease.
3) Determining optimal treatment approaches for platinum-sensitive versus platinum-resistant recurrent ovarian cancer.
This document provides an introduction and overview for a webinar on molecular and genetic tumor testing for colorectal cancer. It discusses the importance of tumor testing to help determine treatment for stages II-IV colorectal cancer and highlights several key biomarkers such as KRAS, NRAS, BRAF and MSI status that can help predict response to targeted therapies like EGFR inhibitors and determine optimal treatment strategies. The webinar aims to explain how molecular profiling of tumors can personalized treatment decisions and improve outcomes for colorectal cancer patients.
Adjuvant Treatment of Pancreatic Cancer - August 2018Amr Sakr
This document summarizes the history and results of several major clinical trials evaluating different adjuvant treatment strategies for pancreatic cancer after surgical resection. It finds that adjuvant chemotherapy provides a survival benefit compared to observation alone. Specifically, gemcitabine alone and gemcitabine plus capecitabine were found to improve overall and disease-free survival compared to older regimens or observation. Most recently, a modified FOLFIRINOX regimen was shown to provide the longest median and 3-year survival compared to gemcitabine alone, establishing it as the new standard first-line adjuvant treatment for resectable pancreatic cancer when tolerability allows.
This document summarizes a presentation on controversies in hepatobiliary pancreatic surgery. It discusses 4 topics: 1) Whether resectable hilar cholangiocarcinoma should be resected or treated with orthotopic liver transplantation, 2) How to treat node-positive intrahepatic cholangiocarcinoma, 3) Options for unresectable intrahepatic cholangiocarcinoma, and 4) Managing large hepatocellular carcinoma in early cirrhosis. For each topic, one or more case examples are described and various treatment approaches are outlined and discussed. Supporting data from studies on outcomes with different strategies are also presented.
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...Mauricio Lema
Ponencia en el primer simposio de la Asociación Colombiana de Hematología y Oncología (ACHO) de cáncer genitourinario, Bogotá, septiembre 23 y 24 de 2016.
1) The document discusses treatment strategies for metastatic colorectal cancer (mCRC), including the importance of multidisciplinary teams, sequencing of chemotherapy and targeted therapies, and continuing treatment beyond progression.
2) Key points addressed include using oxaliplatin or irinotecan as the chemotherapy backbone, adding targeted therapies like bevacizumab or anti-EGFR antibodies based on molecular markers, and exploring more intensive strategies like FOLFOXIRI for certain patients.
3) Maintaining quality of life across all treatment lines is emphasized as the overarching goal.
This study investigated long-term survival outcomes of 320 patients who underwent radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) or colorectal liver metastases (CLM) between 1999-2010. Minimum 5-year follow-up data was available for 89% of patients, with median follow-up of 115.3 months. For HCC patients, 5-year and 10-year overall survival rates were 38.5% and 23.4%. For CLM patients, 5-year and 10-year overall survival rates were 27.6% and 15%. The study concludes RFA can provide 10-year overall survival rates of over 23% for HCC and 15% for CLM
Ghassan Abou-Alfa, MD, MBA, Robin K. (“Katie”) Kelley, MD, Professor Riccardo Lencioni, MD, FSIR, EBIR, and Amit Singal, MD, MS, prepared useful practice aids pertaining to HCC for this CME/MOC activity titled, "Composing Personalized HCC Treatment Strategies: Insights on Harmonizing Patient Care With a Multidisciplinary Ensemble." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at http://bit.ly/2kAyqO9. CME/MOC credit will be available until November 5, 2020.
The document discusses several controversies in treating recurrent ovarian cancer, including:
1) The role of monitoring CA-125 levels and whether chemotherapy should be initiated based on a rising CA-125 alone without other evidence of disease.
2) The potential benefit of secondary cytoreduction surgery for some patients with recurrent disease.
3) Determining optimal treatment approaches for platinum-sensitive versus platinum-resistant recurrent ovarian cancer.
This document provides an introduction and overview for a webinar on molecular and genetic tumor testing for colorectal cancer. It discusses the importance of tumor testing to help determine treatment for stages II-IV colorectal cancer and highlights several key biomarkers such as KRAS, NRAS, BRAF and MSI status that can help predict response to targeted therapies like EGFR inhibitors and determine optimal treatment strategies. The webinar aims to explain how molecular profiling of tumors can personalized treatment decisions and improve outcomes for colorectal cancer patients.
Adjuvant Treatment of Pancreatic Cancer - August 2018Amr Sakr
This document summarizes the history and results of several major clinical trials evaluating different adjuvant treatment strategies for pancreatic cancer after surgical resection. It finds that adjuvant chemotherapy provides a survival benefit compared to observation alone. Specifically, gemcitabine alone and gemcitabine plus capecitabine were found to improve overall and disease-free survival compared to older regimens or observation. Most recently, a modified FOLFIRINOX regimen was shown to provide the longest median and 3-year survival compared to gemcitabine alone, establishing it as the new standard first-line adjuvant treatment for resectable pancreatic cancer when tolerability allows.
This document summarizes a presentation on controversies in hepatobiliary pancreatic surgery. It discusses 4 topics: 1) Whether resectable hilar cholangiocarcinoma should be resected or treated with orthotopic liver transplantation, 2) How to treat node-positive intrahepatic cholangiocarcinoma, 3) Options for unresectable intrahepatic cholangiocarcinoma, and 4) Managing large hepatocellular carcinoma in early cirrhosis. For each topic, one or more case examples are described and various treatment approaches are outlined and discussed. Supporting data from studies on outcomes with different strategies are also presented.
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...Mauricio Lema
Ponencia en el primer simposio de la Asociación Colombiana de Hematología y Oncología (ACHO) de cáncer genitourinario, Bogotá, septiembre 23 y 24 de 2016.
1) The document discusses treatment strategies for metastatic colorectal cancer (mCRC), including the importance of multidisciplinary teams, sequencing of chemotherapy and targeted therapies, and continuing treatment beyond progression.
2) Key points addressed include using oxaliplatin or irinotecan as the chemotherapy backbone, adding targeted therapies like bevacizumab or anti-EGFR antibodies based on molecular markers, and exploring more intensive strategies like FOLFOXIRI for certain patients.
3) Maintaining quality of life across all treatment lines is emphasized as the overarching goal.
This study investigated long-term survival outcomes of 320 patients who underwent radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) or colorectal liver metastases (CLM) between 1999-2010. Minimum 5-year follow-up data was available for 89% of patients, with median follow-up of 115.3 months. For HCC patients, 5-year and 10-year overall survival rates were 38.5% and 23.4%. For CLM patients, 5-year and 10-year overall survival rates were 27.6% and 15%. The study concludes RFA can provide 10-year overall survival rates of over 23% for HCC and 15% for CLM
Ghassan Abou-Alfa, MD, MBA, Robin K. (“Katie”) Kelley, MD, Professor Riccardo Lencioni, MD, FSIR, EBIR, and Amit Singal, MD, MS, prepared useful practice aids pertaining to HCC for this CME/MOC activity titled, "Composing Personalized HCC Treatment Strategies: Insights on Harmonizing Patient Care With a Multidisciplinary Ensemble." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at http://bit.ly/2kAyqO9. CME/MOC credit will be available until November 5, 2020.
Hepatocellular & Pancreatic CarcinomasRHMBONCO
The document discusses hepatocellular carcinoma (HCC) and pancreatic cancer, including their epidemiology, risk factors, screening, diagnosis, staging, and management. For HCC, risk factors include hepatitis and other liver diseases, while targeted therapies such as sorafenib have shown efficacy. Surgical resection can cure early HCC but recurrence is common. For pancreatic cancer, risk increases with age and genetic factors, while surgery offers the only chance for cure if the cancer is resectable.
This document summarizes targeted therapies for ovarian cancer, including anti-angiogenic agents and PARP inhibitors. It discusses several studies evaluating bevacizumab, an anti-VEGF monoclonal antibody, in the first-line and recurrent platinum-sensitive settings. The GOG218 and ICON7 trials showed improved progression-free survival when bevacizumab was added to first-line chemotherapy. The OCEANS trial demonstrated significantly longer progression-free and overall survival with the addition of bevacizumab to chemotherapy for platinum-sensitive recurrent ovarian cancer. Adverse events with bevacizumab were consistent with its known safety profile.
Terapia sistémica en cáncer de testículoMauricio Lema
The document discusses treatment options for testicular cancer, including surveillance, radiotherapy, carboplatin chemotherapy, and cisplatin-based chemotherapy. It provides details on clinical trials comparing radiotherapy and carboplatin for stage I seminoma, and evaluates outcomes and toxicities. The document also reviews management of advanced or metastatic testicular cancer with carboplatin or cisplatin-based regimens along with the role of PET scanning in response assessment.
- The document discusses liver and hepatobiliary cancers, focusing on hepatocellular carcinoma (HCC). It covers the epidemiology, risk factors, screening and diagnosis of HCC as well as staging systems and treatment options.
- Risk factors for HCC include hepatitis B and C infection, alcohol consumption, and aflatoxin intake. Screening ultrasound and AFP tests are used for early diagnosis in high-risk patients. The BCLC staging system guides treatment which includes resection, transplantation, ablation, and embolization.
- For intermediate stage HCC, transarterial chemoembolization provides the best outcomes, with 70-80% of patients surviving 1 year and 50% surviving 3 years. However
FIRE 3 Trail FOLFIRI+Cetuximab Vs FOLFIRI+BevacizumabAhmed Allam
This randomized, open-label, phase 3 trial compared FOLFIRI plus cetuximab (C+F) versus FOLFIRI plus bevacizumab (B+F) as first-line treatment for KRAS wild-type metastatic colorectal cancer. The trial found that C+F resulted in improved progression-free survival and overall survival compared to B+F. C+F was associated with increased rates of acneiform rash, paronychia, and hypomagnesemia but similar rates of other adverse events compared to B+F. The trial demonstrated that for patients with KRAS wild-type mCRC, first-line treatment with C+F provided superior
This study evaluated the roles of adjuvant chemoradiotherapy and chemotherapy in patients with resected pancreatic cancer. 541 patients were randomized to one of four groups: chemoradiotherapy, chemotherapy, both, or observation. The results showed no survival benefit for adjuvant chemoradiotherapy, with a median survival of 15.5 months compared to 16.1 months without chemoradiotherapy. However, there was evidence of a survival benefit for adjuvant chemotherapy, with a median survival of 19.7 months compared to 14 months without chemotherapy. This study provided evidence that adjuvant chemotherapy may improve survival for patients with resected pancreatic cancer, but did not show a benefit for chemoradiotherapy.
Each summer, the American Society for Clinical Oncology holds the world’s largest conference for cancer researchers, doctors and other medical professionals. Results from clinical trials and other studies are released, which give scientists a fresh look at treatments that may or may not hold great promise in the march toward a cure for cancer.
Dr. Axel Grothey of the Mayo Clinic will explain what science is now telling us about colorectal cancer and how it may impact your treatment in the near future.
Second line chemotherapy for ovarian cancerBasalama Ali
This document discusses second line chemotherapy options for ovarian cancer. It defines platinum-sensitive and platinum-resistant disease based on platinum-free interval. For platinum-sensitive disease, retreatment with the same regimen or a combination is recommended over single agent. Bevacizumab added to chemotherapy improves outcomes for platinum-resistant disease. While further lines of therapy can improve survival, patient performance status must be considered.
This document summarizes the optimal treatment of ovarian cancer. It presents two case studies, the first involving a 59-year-old woman with stage III ovarian cancer, and the second involving a 62-year-old woman with recurrent ovarian cancer. For the first case, the document suggests that paclitaxel plus carboplatin is the optimal initial treatment. For the recurrent case, it discusses whether debulking surgery is appropriate and different chemotherapy options. The document then outlines milestones in ovarian cancer treatment and strategies for improving outcomes, including increasing optimal debulking rates, adding new drugs, dose-dense therapy, targeted therapies like bevacizumab, and intraperitoneal chemotherapy.
The document discusses the role of chemotherapy in carcinoma of the stomach. It outlines several key trials investigating neoadjuvant, adjuvant and perioperative chemotherapy approaches. The MAGIC trial showed significantly improved 5-year survival with perioperative chemotherapy compared to surgery alone. The French FNCLCC trial also demonstrated improved disease-free and overall survival with perioperative chemotherapy. Adjuvant chemoradiation was shown in the INT0116/SWOG 9008 trial to improve 5-year overall and disease-free survival compared to surgery alone. The Japanese S-1 trial found significant benefit in 5-year disease-free and overall survival with adjuvant S-1 chemotherapy compared to observation after surgery.
Estado actual de terapia sistémica en cáncer renal metastásicoMauricio Lema
This document discusses the current management of metastatic renal cell carcinoma (mRCC). It provides an overview of targeted therapies for mRCC including tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and cabozantinib that target the VEGF pathway. Clinical trial results are presented comparing TKIs in first-line mRCC. Active surveillance is also discussed as a treatment option for select asymptomatic or minimally symptomatic mRCC patients. Toxicities of TKIs like fatigue, diarrhea and hand-foot syndrome are reviewed along with their negative impact on quality of life.
HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advan...REBRATSoficial
This document summarizes a cost-effectiveness analysis of treatment strategies for metastatic colorectal cancer in Brazil. It finds that adding monoclonal antibodies like bevacizumab and cetuximab to chemotherapy improves survival but that the strategies are not cost-effective in Brazil's public health system as the cost per life year gained is over the hypothetical threshold of 3 times GDP per capita. The analysis uses a Markov model to compare costs and outcomes of 3 treatment sequences over a lifetime, finding that chemotherapy alone without antibodies has the best cost-effectiveness profile.
*Based on retrospective analysis of 2018 patients from the First BEAT trial
Okines A, et al. Br J Cancer. 2009;101:1033-1038.
*Clinical practice refers to outcomes seen in a large clinical trial, not necessarily guidelines.
Treating the Patient With Newly Diagnosed Metastatic Colorectal Cancer
clinicaloptions.com/oncology
Recommended Treatment Plan
FOLFOXIRI + bevacizumab for 6 months as neoadjuvant
therapy
Re-evaluate for resection after 3 months of therapy
If resection possible after 6 months, proceed with
resection
Options in platinum-resistant ovarian cancerMauricio Lema
- Options for treating platinum-resistant ovarian cancer (PROC) are limited. Chemotherapy options include topotecan, pegylated liposomal doxorubicin, and paclitaxel, with response rates of around 15% and progression-free survival of approximately 3 months. Bevacizumab combined with chemotherapy improves response rates to around 27% and progression-free survival to about 6 months. PARP inhibitors such as olaparib have response rates of around 30% in patients with BRCA mutations. Immunotherapy and hormone therapy are also being investigated. Several new targeted agents including WEE1 and folate receptor alpha inhibitors show promise.
Chair and Presenter, Prof Eric Van Cutsem, MD, PhD, and Scott Kopetz, MD, PhD, prepared useful Practice Aids pertaining to colorectal cancer for this CME/MOC/NCPD activity titled “Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at https://bit.ly/3aSSAtm. CME/MOC/NCPD credit will be available until November 13, 2022.
This document discusses genetics implications for survivorship programs. It highlights identifying patients who were previously missed for genetic testing and may benefit from re-testing given advances in panel testing. It also reviews managing hereditary cancer risks and addressing the psychosocial issues patients face, such as making difficult medical decisions, informing relatives, and dealing with feelings of guilt. Survivorship programs can help such patients navigate these medical and familial implications.
Olaparib in Metastatic Pancreatic Cancer Chandan K Das
The POLO trial was a randomized, double-blind, placebo-controlled study that evaluated olaparib maintenance therapy in patients with gBRCAm metastatic pancreatic cancer who had not progressed after first-line platinum-based chemotherapy. The study enrolled 154 patients from 12 countries between 2015-2019. The primary endpoint was progression-free survival assessed by blinded independent central review. Key results showed a statistically significant improvement in progression-free survival in the olaparib arm compared to placebo.
This document summarizes results from several clinical trials presented at the ASCO 2014 conference on gastrointestinal oncology:
- The CALGB/SWOG 80405 trial found that first-line chemotherapy with FOLFOX plus either bevacizumab or cetuximab resulted in similar progression-free and overall survival in patients with KRAS wild-type metastatic colorectal cancer.
- The STORM trial found that adjuvant sorafenib after resection or ablation of hepatocellular carcinoma did not improve recurrence-free survival compared to placebo, with significant treatment-related adverse events in the sorafenib group.
- The LAP 07 study evaluated the addition of radiotherapy after induction chemotherapy for
Pancreatic Cancer Are We Moving Forward Yetfondas vakalis
This summary provides an overview of key findings from studies presented at the 2007 Gastrointestinal Cancers Symposium on treatments for pancreatic cancer:
1) A phase III trial found that adding bevacizumab to gemcitabine did not improve survival for advanced pancreatic cancer.
2) A phase II study showed promising results for cetuximab plus gemcitabine/oxaliplatin, with a high response rate and tolerable toxicity.
3) Population-based analyses found adjuvant radiotherapy after surgery and chemo-radiotherapy improved survival outcomes for pancreatic cancer.
An Interesting case of metastatic Clear cell carcinoma ovary treated with tar...Alok Gupta
Dr. Alok Gupta presents two interesting clinical cases. Case 1 involves a 59-year-old woman with relapsed ovarian clear cell carcinoma who had progressed through five lines of therapy. She was started on pazopanib, a targeted therapy, and showed an ongoing partial response for over a year. Case 2 involves a 58-year-old woman presenting with esophageal cancer who was also found to have synchronous colorectal cancer. She received neoadjuvant chemotherapy, followed by surgery to remove both cancers, and remains disease-free after two years of follow up and adjuvant chemotherapy. Both cases demonstrate successful treatment approaches for difficult cancer cases.
Hepatocellular & Pancreatic CarcinomasRHMBONCO
The document discusses hepatocellular carcinoma (HCC) and pancreatic cancer, including their epidemiology, risk factors, screening, diagnosis, staging, and management. For HCC, risk factors include hepatitis and other liver diseases, while targeted therapies such as sorafenib have shown efficacy. Surgical resection can cure early HCC but recurrence is common. For pancreatic cancer, risk increases with age and genetic factors, while surgery offers the only chance for cure if the cancer is resectable.
This document summarizes targeted therapies for ovarian cancer, including anti-angiogenic agents and PARP inhibitors. It discusses several studies evaluating bevacizumab, an anti-VEGF monoclonal antibody, in the first-line and recurrent platinum-sensitive settings. The GOG218 and ICON7 trials showed improved progression-free survival when bevacizumab was added to first-line chemotherapy. The OCEANS trial demonstrated significantly longer progression-free and overall survival with the addition of bevacizumab to chemotherapy for platinum-sensitive recurrent ovarian cancer. Adverse events with bevacizumab were consistent with its known safety profile.
Terapia sistémica en cáncer de testículoMauricio Lema
The document discusses treatment options for testicular cancer, including surveillance, radiotherapy, carboplatin chemotherapy, and cisplatin-based chemotherapy. It provides details on clinical trials comparing radiotherapy and carboplatin for stage I seminoma, and evaluates outcomes and toxicities. The document also reviews management of advanced or metastatic testicular cancer with carboplatin or cisplatin-based regimens along with the role of PET scanning in response assessment.
- The document discusses liver and hepatobiliary cancers, focusing on hepatocellular carcinoma (HCC). It covers the epidemiology, risk factors, screening and diagnosis of HCC as well as staging systems and treatment options.
- Risk factors for HCC include hepatitis B and C infection, alcohol consumption, and aflatoxin intake. Screening ultrasound and AFP tests are used for early diagnosis in high-risk patients. The BCLC staging system guides treatment which includes resection, transplantation, ablation, and embolization.
- For intermediate stage HCC, transarterial chemoembolization provides the best outcomes, with 70-80% of patients surviving 1 year and 50% surviving 3 years. However
FIRE 3 Trail FOLFIRI+Cetuximab Vs FOLFIRI+BevacizumabAhmed Allam
This randomized, open-label, phase 3 trial compared FOLFIRI plus cetuximab (C+F) versus FOLFIRI plus bevacizumab (B+F) as first-line treatment for KRAS wild-type metastatic colorectal cancer. The trial found that C+F resulted in improved progression-free survival and overall survival compared to B+F. C+F was associated with increased rates of acneiform rash, paronychia, and hypomagnesemia but similar rates of other adverse events compared to B+F. The trial demonstrated that for patients with KRAS wild-type mCRC, first-line treatment with C+F provided superior
This study evaluated the roles of adjuvant chemoradiotherapy and chemotherapy in patients with resected pancreatic cancer. 541 patients were randomized to one of four groups: chemoradiotherapy, chemotherapy, both, or observation. The results showed no survival benefit for adjuvant chemoradiotherapy, with a median survival of 15.5 months compared to 16.1 months without chemoradiotherapy. However, there was evidence of a survival benefit for adjuvant chemotherapy, with a median survival of 19.7 months compared to 14 months without chemotherapy. This study provided evidence that adjuvant chemotherapy may improve survival for patients with resected pancreatic cancer, but did not show a benefit for chemoradiotherapy.
Each summer, the American Society for Clinical Oncology holds the world’s largest conference for cancer researchers, doctors and other medical professionals. Results from clinical trials and other studies are released, which give scientists a fresh look at treatments that may or may not hold great promise in the march toward a cure for cancer.
Dr. Axel Grothey of the Mayo Clinic will explain what science is now telling us about colorectal cancer and how it may impact your treatment in the near future.
Second line chemotherapy for ovarian cancerBasalama Ali
This document discusses second line chemotherapy options for ovarian cancer. It defines platinum-sensitive and platinum-resistant disease based on platinum-free interval. For platinum-sensitive disease, retreatment with the same regimen or a combination is recommended over single agent. Bevacizumab added to chemotherapy improves outcomes for platinum-resistant disease. While further lines of therapy can improve survival, patient performance status must be considered.
This document summarizes the optimal treatment of ovarian cancer. It presents two case studies, the first involving a 59-year-old woman with stage III ovarian cancer, and the second involving a 62-year-old woman with recurrent ovarian cancer. For the first case, the document suggests that paclitaxel plus carboplatin is the optimal initial treatment. For the recurrent case, it discusses whether debulking surgery is appropriate and different chemotherapy options. The document then outlines milestones in ovarian cancer treatment and strategies for improving outcomes, including increasing optimal debulking rates, adding new drugs, dose-dense therapy, targeted therapies like bevacizumab, and intraperitoneal chemotherapy.
The document discusses the role of chemotherapy in carcinoma of the stomach. It outlines several key trials investigating neoadjuvant, adjuvant and perioperative chemotherapy approaches. The MAGIC trial showed significantly improved 5-year survival with perioperative chemotherapy compared to surgery alone. The French FNCLCC trial also demonstrated improved disease-free and overall survival with perioperative chemotherapy. Adjuvant chemoradiation was shown in the INT0116/SWOG 9008 trial to improve 5-year overall and disease-free survival compared to surgery alone. The Japanese S-1 trial found significant benefit in 5-year disease-free and overall survival with adjuvant S-1 chemotherapy compared to observation after surgery.
Estado actual de terapia sistémica en cáncer renal metastásicoMauricio Lema
This document discusses the current management of metastatic renal cell carcinoma (mRCC). It provides an overview of targeted therapies for mRCC including tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and cabozantinib that target the VEGF pathway. Clinical trial results are presented comparing TKIs in first-line mRCC. Active surveillance is also discussed as a treatment option for select asymptomatic or minimally symptomatic mRCC patients. Toxicities of TKIs like fatigue, diarrhea and hand-foot syndrome are reviewed along with their negative impact on quality of life.
HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advan...REBRATSoficial
This document summarizes a cost-effectiveness analysis of treatment strategies for metastatic colorectal cancer in Brazil. It finds that adding monoclonal antibodies like bevacizumab and cetuximab to chemotherapy improves survival but that the strategies are not cost-effective in Brazil's public health system as the cost per life year gained is over the hypothetical threshold of 3 times GDP per capita. The analysis uses a Markov model to compare costs and outcomes of 3 treatment sequences over a lifetime, finding that chemotherapy alone without antibodies has the best cost-effectiveness profile.
*Based on retrospective analysis of 2018 patients from the First BEAT trial
Okines A, et al. Br J Cancer. 2009;101:1033-1038.
*Clinical practice refers to outcomes seen in a large clinical trial, not necessarily guidelines.
Treating the Patient With Newly Diagnosed Metastatic Colorectal Cancer
clinicaloptions.com/oncology
Recommended Treatment Plan
FOLFOXIRI + bevacizumab for 6 months as neoadjuvant
therapy
Re-evaluate for resection after 3 months of therapy
If resection possible after 6 months, proceed with
resection
Options in platinum-resistant ovarian cancerMauricio Lema
- Options for treating platinum-resistant ovarian cancer (PROC) are limited. Chemotherapy options include topotecan, pegylated liposomal doxorubicin, and paclitaxel, with response rates of around 15% and progression-free survival of approximately 3 months. Bevacizumab combined with chemotherapy improves response rates to around 27% and progression-free survival to about 6 months. PARP inhibitors such as olaparib have response rates of around 30% in patients with BRCA mutations. Immunotherapy and hormone therapy are also being investigated. Several new targeted agents including WEE1 and folate receptor alpha inhibitors show promise.
Chair and Presenter, Prof Eric Van Cutsem, MD, PhD, and Scott Kopetz, MD, PhD, prepared useful Practice Aids pertaining to colorectal cancer for this CME/MOC/NCPD activity titled “Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at https://bit.ly/3aSSAtm. CME/MOC/NCPD credit will be available until November 13, 2022.
This document discusses genetics implications for survivorship programs. It highlights identifying patients who were previously missed for genetic testing and may benefit from re-testing given advances in panel testing. It also reviews managing hereditary cancer risks and addressing the psychosocial issues patients face, such as making difficult medical decisions, informing relatives, and dealing with feelings of guilt. Survivorship programs can help such patients navigate these medical and familial implications.
Olaparib in Metastatic Pancreatic Cancer Chandan K Das
The POLO trial was a randomized, double-blind, placebo-controlled study that evaluated olaparib maintenance therapy in patients with gBRCAm metastatic pancreatic cancer who had not progressed after first-line platinum-based chemotherapy. The study enrolled 154 patients from 12 countries between 2015-2019. The primary endpoint was progression-free survival assessed by blinded independent central review. Key results showed a statistically significant improvement in progression-free survival in the olaparib arm compared to placebo.
This document summarizes results from several clinical trials presented at the ASCO 2014 conference on gastrointestinal oncology:
- The CALGB/SWOG 80405 trial found that first-line chemotherapy with FOLFOX plus either bevacizumab or cetuximab resulted in similar progression-free and overall survival in patients with KRAS wild-type metastatic colorectal cancer.
- The STORM trial found that adjuvant sorafenib after resection or ablation of hepatocellular carcinoma did not improve recurrence-free survival compared to placebo, with significant treatment-related adverse events in the sorafenib group.
- The LAP 07 study evaluated the addition of radiotherapy after induction chemotherapy for
Pancreatic Cancer Are We Moving Forward Yetfondas vakalis
This summary provides an overview of key findings from studies presented at the 2007 Gastrointestinal Cancers Symposium on treatments for pancreatic cancer:
1) A phase III trial found that adding bevacizumab to gemcitabine did not improve survival for advanced pancreatic cancer.
2) A phase II study showed promising results for cetuximab plus gemcitabine/oxaliplatin, with a high response rate and tolerable toxicity.
3) Population-based analyses found adjuvant radiotherapy after surgery and chemo-radiotherapy improved survival outcomes for pancreatic cancer.
An Interesting case of metastatic Clear cell carcinoma ovary treated with tar...Alok Gupta
Dr. Alok Gupta presents two interesting clinical cases. Case 1 involves a 59-year-old woman with relapsed ovarian clear cell carcinoma who had progressed through five lines of therapy. She was started on pazopanib, a targeted therapy, and showed an ongoing partial response for over a year. Case 2 involves a 58-year-old woman presenting with esophageal cancer who was also found to have synchronous colorectal cancer. She received neoadjuvant chemotherapy, followed by surgery to remove both cancers, and remains disease-free after two years of follow up and adjuvant chemotherapy. Both cases demonstrate successful treatment approaches for difficult cancer cases.
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Clinical outcome, proteome kinetics and angiogenic factors in serum after the...Enrique Moreno Gonzalez
Thermoablation is used to treat patients with unresectable colorectal liver metastases (CRLM). We analyze clinical outcome, proteome kinetics and angiogenic markers in patients treated by cryosurgical ablation (CSA) or radiofrequency ablation (RFA).
1. Ovarian cancer is the second most common gynecologic malignancy in the US, with most cases presenting at advanced stages.
2. Recurrent disease is common, even after initial treatment, and targeting angiogenesis through VEGF inhibition has shown promising results both as single agent therapy and in combination with chemotherapy.
3. Bevacizumab has been approved as front-line treatment combined with chemotherapy based on improved progression-free survival seen in clinical trials, though no overall survival benefit has been proven.
Alpha-Fetoprotein and the Early Diagnosis of Hepatocellular CarcinomaJohnJulie1
Hepatocellular carcinoma is the most common primary malignant tumor of the liver. Cirrhosisis associated with its carcinogenesis, so periodic surveillance is necessary. Ultrasonography is currently the most appropriate test for screening hepatocellular carcinoma, and alpha-fetoprotein is the most used biomarker despite its low sensitivity
Similar to Gastrointestinal Cancer: Research & Therapy (6)
Austin Journal of Robotics & Automation is an international scholarly, peer review, Open Access journal, initiated with an aim to promote the research in Robotics & Automation, which deals with design, construction, operation, and application of robots.
Austin Journal of Robotics & Automation is a comprehensive Open Access peer reviewed scientific journal that covers multidisciplinary fields. We provide limitless access towards accessing our literature hub with colossal range of articles. The journal aims to publish high quality varied article types such as Research, Review, Short Communications, Case Reports, Perspectives (Editorials).
Austin Journal of Robotics & Automation supports the scientific modernization and enrichment in Robotics & Automation research community by magnifying access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed member journals under one roof thereby promoting knowledge sharing, collaborative and promotion of multidisciplinary technology.
Austin Journal of Multiple Sclerosis & Neuroimmunology is an open access, peer review Journal publishing original research & review articles on aetiology, epidemiology, and pathogenesis of inflammatory demyelinating diseases of the central nervous system. Austin Journal of Multiple Sclerosis & Neuroimmunology is aimed to provide a strong platform for challenging cases that includes but not excludes the damage of insulating covers of both central nervous system and spine. It is a grounding platform for all neurologists, neuroimmunologists, neurovirologists, researchers, medical doctors, health professionals, scientists, and scholars to publish their research work & update the latest research information.
Topics include but not limited to Clinical Neurology, Biomarkers, Glial, Myelin Chemistry, Neuroimaging, Neuropathology, Neuroepidemiology, Therapeutics, Genetics/Transcriptomics, Experimental Models, Pathobiology, Neuroimmunology, Neuropsychology, Neurorehabilitation, Pathobiology of the Brain, Psychology, Measurement Scales, Teaching, and Neuroethics.
Austin Journal of Multiple Sclerosis & Neuroimmunology supports the scientific transformation and fortification in Medical and Clinical research community by magnifying access to peer reviewed scientific literary works. Austin also brings universally peer reviewed member journals under one roof thereby promoting knowledge sharing, collaborative and promotion of multidisciplinary science.
Austin Leukemia is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Leukemia.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Leukemia. Austin Leukemia accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Leukemia.
Austin Leukemia strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Autism impacts normal brain development in areas of social interaction and communication. People with autism may exhibit repetitive behaviors, unusual responses to people, attachment to objects, and resistance to change in routine. The main types of autism are autistic disorder, Asperger's disorder, pervasive developmental disorder, Rett's disorder, and childhood disintegrative disorder, which are distinguished based on levels of impairment and when symptoms begin. While there is no definitive medical test, autism is diagnosed by a team using interviews, observations, and checklists to evaluate social skills, communication, and restricted or repetitive behaviors.
Austin Journal of Asthma: Open Access is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Asthma.
The journal aims to promote latest information and provide a forum for doctors, researchers, physicians, and healthcare professionals to find most recent advances in the areas of Asthma. Austin Journal of Asthma: Open Access accepts research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Asthma.
Austin Journal of Asthma: Open Access strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing.
Austin Journal of Anesthesia and Analgesia is an open access, peer reviewed, scholarly journal dedicated to publish articles in all areas of anesthesiology and pain management.
The aim of the journal is to provide a forum for anesthesiologists, researchers, physicians, and other health professionals to find most recent advances in the areas of anesthesiology. Austin Journal of Anesthesia and Analgesia accepts original research articles, review articles, case reports and rapid communication on all the aspects of anesthesiology and pain management.
Austin Journal of Anesthesia and Analgesia strongly supports the scientific upgradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Austin Journal of Accounting, Audit and Finance Management is a peer reviewed open access journal in publishes manuscripts from all the areas of accounting, accountancy, finance, auditing.
Austin Journal of Accounting, Audit and Finance Management Original Articles, Review, Discussion, Editorials, Letter, type of manuscripts from all the areas of the accounting, accountancy, finance, auditing.
Austin Virology and Retrovirology is an international scholarly peer reviewed Open Access journal, aims to promote the research in the field of Virology.
Austin Virology and Retrovirology is a comprehensive Open Access peer reviewed scientific Journal that covers multidisciplinary fields. We provide limitless access towards accessing our literature hub with colossal range of articles. The journal aims to publish high quality varied article types such as Research, Review, Case Reports, Short Communications, Perspectives (Editorials), Clinical Images
Austin Virology and Retrovirology supports the scientific modernization and enrichment in virology research community by magnifying access to peer reviewed scientific literary works. Austin also brings universally peer reviewed member journals under one roof thereby promoting knowledge sharing, collaborative and promotion of multidisciplinary science.
Austin Journal of Urology is an open access, peer reviewed, scholarly journal dedicated to publish articles in all areas of Urology.
The aim of the journal is to provide a forum for urologists, nephrologists, research scholars, physicians, and other healthcare professionals to find most recent advances in the field of Urology.
Austin Journal of Urology accepts original research articles, review articles, case reports and short communication on all the aspects of Urology and relevant basic science issues.
Annals of Thyroid Research is a peer-reviewed, open access journal published by Austin Publishers. It provides easy access to high quality Manuscripts in all related aspects of thyroid hormones and thyroid diseases and their interaction with the cardiovascular system, pulmonary system, gastroenteron system, metabolic and nervous systems. The journal also focuses upon all the thyroid disease symptoms and treatments, including hyperthyroid and hypothyroid, plus a range of other thyroid problems including thyroid cancer.
Austin Publishing Group is a successful host of more than hundred peer reviewed, open access journals in various fields of science and medicine with intent to bridge the gap between academia and research access.
Annals of Thyroid Research accepts original research articles, review articles, case reports, mini reviews, rapid communication, opinions and editorials on all related aspects of all related aspects of thyroid hormones and thyroid diseases.
Austin Journal of Robotics & Automation is an international scholarly, peer review, Open Access journal, initiated with an aim to promote the research in Robotics & Automation, which deals with design, construction, operation, and application of robots.
Austin Journal of Robotics & Automation is a comprehensive Open Access peer reviewed scientific journal that covers multidisciplinary fields. We provide limitless access towards accessing our literature hub with colossal range of articles. The journal aims to publish high quality varied article types such as Research, Review, Short Communications, Case Reports, Perspectives (Editorials).
Austin Journal of Robotics & Automation supports the scientific modernization and enrichment in Robotics & Automation research community by magnifying access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed member journals under one roof thereby promoting knowledge sharing, collaborative and promotion of multidisciplinary technology.
Austin Journal of Orthopedics & Rheumatology is an open access, peer reviewed, scholarly journal dedicated to publish articles in all areas of Orthopedics.
The aim of the journal is to provide a forum for orthopedicians, researchers, physicians, and other health professionals to find most recent advances in the areas of Orthopedics.
Austin Journal of Orthopedics & Rheumatology accepts original research articles, review articles, case reports and rapid communication on all the aspects of Orthopedics and its related areas.
Austin Pediatrics is an open access, peer reviewed, scholarly journal committed to publish articles in all areas of science and practice of Pediatrics.
The aspire of the journal is to present a platform for scientists and academicians all over the world to encourage, distribute, and discuss various new issues and developments in different areas of Pediatrics and to promote responsible and balanced debate on controversial issues that influence child health, including non-clinical areas such as ethics, law, surroundings and economics.
Austin Pediatrics accepts innovative research articles, review articles, case reports and rapid communication on all the aspects of Pediatrics.
Austin Pediatrics is an open access, peer reviewed, scholarly journal committed to publish articles in all areas of science and practice of Pediatrics.
Austin Otolaryngology is an open access, peer review journal publishing original research & review articles in all the fields of Otolaryngology. Otolaryngology deals with the study of ear, nose and throat. Austin Otolaryngology provides a new platform for students to publish their research work & update the latest research information in Otolaryngology.
Austin Otolaryngology is a comprehensive Open Access peer reviewed scientific Journal that covers multidisciplinary fields. We provide limitless access towards accessing our literature hub with colossal range of articles. The journal aims to publish high quality varied article types such as Research, Review, Short Communications, Case Reports, Perspectives (Editorials), Clinical Images.
Austin Otolaryngology supports the scientific modernization and enrichment in Otolaryngology research community by magnifying access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed member journals under one roof thereby promoting knowledge sharing, collaborative and promotion of multidisciplinary science.
Clinics in Oncology Research is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of oncology.
The journal aims to promote latest information and provide a forum for oncologists, doctors, researchers, physicians, and healthcare professionals to find most recent advances in the areas of oncology. Clinics in Oncology Research accepts research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of oncology.
Clinics in Oncology Research strongly support the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing.
Austin Journal of Obesity & Metabolic Syndrome is an international scholarly peer reviewed Open Access journal, aims to promote the research in all the related fields of Metabolic Syndrome.
Austin Journal of Obesity & Metabolic Syndrome is a comprehensive Open Access peer reviewed scientific Journal that covers multidisciplinary fields. We provide limitless access towards accessing our literature hub with colossal range of articles. The journal aims to publish high quality varied article types such as Research, Review, Short Communications, Case Reports, Perspectives (Editorials), Clinical Images.
Austin Journal of Obesity & Metabolic Syndrome supports the scientific modernization and enrichment in Metabolic Syndromes research community by magnifying access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed member journals under one roof thereby promoting knowledge sharing, collaborative and promotion of multidisciplinary science.
Austin Journal of Nutrition and Food sciences is an open access, peer reviewed, scholarly journal dedicated to publish articles in all areas of nutrition and food sciences
The aim of the journal is to provide a forum for dietitians, researchers, physicians, and other health professionals to find most recent advances in the areas of clinical nutrition and nutritional disorders.
Austin Journal of Nutrition and Food sciences accepts original research articles, review articles, case reports and rapid communication on all the aspects of internal medicine.
Austin Journal of Clinical Neurology is an open access, peer reviewed, scholarly journal dedicated to publish articles in all areas of neurology, neurophysiology and stroke.
The aim of the journal is to provide a forum for neurologists, researchers, physicians, and other health professionals to find most recent advances in the areas of clinical and experimental neurology. Austin Journal of Clinical Neurology accepts original research articles, review articles, case reports, clinical images and rapid communication on all the aspects of clinical neurology and nervous system diseases.
Austin Journal of Clinical Neurology strongly supports the scientific upgradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Austin Journal of Clinical Neurology is an open access, peer reviewed, scholarly journal dedicated to publish articles in all areas of neurology, neurophysiology and stroke.
Austin Journal of Musculoskeletal Disorders is a peer-reviewed, open access journal published by Austin Publishers. It provides easy access to high quality Manuscripts in all related aspects of diseases and disorders that may adversely affect the function and overall effectiveness of the musculoskeletal system. The Journal focuses upon all the related aspects of musculoskeletal system disorders and the new advancements in the related treatments including Complex issues and injuries involving the musculoskeletal system and surgeries.
Austin Publishing Group is a successful host of more than hundred peer reviewed, open access journals in various fields of science and technology with intent to bridge the gap between academia and research access.
Austin Journal of Musculoskeletal Disorders accepts original research articles, review articles, case reports, mini reviews, rapid communication, opinions and editorials on all related aspects of diseases and disorders that may adversely affect the function and overall effectiveness of the musculoskeletal system.
Austin Hypertension is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Hypertension.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Hypertension. Austin Hypertension accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of hypertension.
Austin Hypertension strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
Chandrima Spa Ajman is one of the leading Massage Center in Ajman, which is open 24 hours exclusively for men. Being one of the most affordable Spa in Ajman, we offer Body to Body massage, Kerala Massage, Malayali Massage, Indian Massage, Pakistani Massage Russian massage, Thai massage, Swedish massage, Hot Stone Massage, Deep Tissue Massage, and many more. Indulge in the ultimate massage experience and book your appointment today. We are confident that you will leave our Massage spa feeling refreshed, rejuvenated, and ready to take on the world.
Visit : https://massagespaajman.com/
Call : 052 987 1315
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)bkling
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
Can Allopathy and Homeopathy Be Used Together in India.pdfDharma Homoeopathy
This article explores the potential for combining allopathy and homeopathy in India, examining the benefits, challenges, and the emerging field of integrative medicine.
2. Gastrointest Cancer Res Ther 2(3): id1024 (2017) - Page - 02
Tsung SH Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
be on capecitabin as maintenance dose. The patient experienced only
grade 2 peripheral neuropathy, and doing very well when he was seen
at his follow-up on July 1, 2017. CT scan showed complete resolution
of liver metastasis (Figure 4). All tumor markers returned to normal
levels (Table 1). Follow-up gastroscopic examination was performed
on March 1, 2017, and failed to demonstrate tumor at the previous
site (Figure 5).
Discussion
Our patient had negative testing for hepatitis B and C. It was
unlikely that he had HCC metastasized to the stomach. Dynamic
computer tomography also confirmed that the lesions in the liver
were from metastasis. Furthermore, his gastric biopsy specimen
showed poorly differentiated adenocarcinoma with markedly
elevated serum level of AFP supporting the diagnosis of AFP-GC.
Negative immunohistochemistry staining on his gastric biopsy
specimen did not negate the diagnosis of AFP-GC. In the literature,
the immunoreactivity for AFP was negative in some reported cases
[11]. The reason could be related to its sensitivity. In our patient,
the serum level of AFP was 16,398ng/ml, sensitivity should not have
been the issue. Another explanation could be due to the limited
sampling [12]. A recent study by Kinjio et al. [13] suggested that
the gastric carcinoma started on the mucosa, which differentiated
into enteroblastic type and hepatoid type. During the process of
tumor invasion and proliferation, the tumor cells acquired the AFP
Figure 1: Gastroscopic examination revealed a polypoid lesion in the cardia
portion of the stomach.
Figure 2: Gastric biopsy specimen showed poorly differentiated
adenocarcinoma (H&E.x400).
Figure 3: Computed tomography (CT) revealed multiple liver metastasis.
Figure 4: Computed tomography 4 months after therapy revealed complete
resolution of liver metastasis.
Date Serum level of CEA (ng/ml) Serum level of AFP (ng/ml)
03/08/2016 107.98 16,390
04/28/2016 55.2 455
06/21/2016 4.0 3.7
07/12/2016 2.6 3.3
08/16/2016 1.8 2.8
12/12/2016 1.9 3.4
Table 1: Serum levels of tumor markers.
CEA: Carcinoembryonic Antigen; AFP: Alpha-fetoprotein.
Figure 5: Followup gastroscopy examination showed a normal mucosa at
the previous tumor site.